Collaboration with ANRT

Sep 10, 2015PRESS RELEASESHit 271

MedPacto Inc. and ANRT have entered into a collaboration agreement for the development of novel biologics and monoclonal antibodies to develop drugs and diagnosis. The collaboration will focus on  the discovery and development of first-in-class therapies and diagnosis tools. Under the terms of the agreement, MedPacto, Inc. will share the outcome from the collaboration with ANRT

Previous Clinical trial of TEW-7197 starts its first step.
Next MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)